For Patients with NSCLC

E4512 Available Through ECOG-ACRIN
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Patient Population
See Section 3.0 for Complete Eligibility Details

- Age ≥ 18 years, ECOG PS 0-1, and adequate lab values.
- Must have undergone complete surgical resection of their stage IIA, IIB, IIIA or IIIB non-squamous or squamous b NSCLC per AJCC 8th and have negative margins. N3 disease is not allowed.
- Baseline chest CT must be performed within 6 months (180) days prior to randomization to ensure no evidence of disease. If clinically indicated additional imaging must be performed to rule out metastatic disease.
- Must be registered to A151216 prior to randomization.
- Must test positive for translocation or inversion events involving the ALK gene locus as determined by the Vysis Break Point FISH assay and defined by an increase in the distance between 5' and 3' ALK probes or the loss of the 5' probe (See protocol section 3.1.6. for more details).
- Must not have uncontrolled intercurrent illness (i.e., serious ongoing/active infection, symptomatic CHF, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- No known interstitial fibrosis or interstitial lung disease.
- No prior treatment with crizotinib or another ALK inhibitor.
- No ongoing cardiac dysrhythmias of Grade ≥ 2 CTCAE v.4.0, uncontrolled A-fib (any grade), or QTc interval > 470 msec.
- No use of medications, herbals, or foods that are known potent CYP3A4 inhibitors/inducers (see Appendix V).
- Must be adequately recovered from surgery at time of randomization (see protocol for details).
- Must have completed any prior adjuvant chemotherapy/RT 2 or more weeks (6 or more weeks for mitomycin/ nitrosoureas) prior to randomization and be adequately recovered.

Treatment Plan
See Section 5.0 for Complete Treatment Details

In order to be eligible for this trial, all patients must have undergone complete resection of the cancer prior to enrollment. Accepted types of resection (with negative margins) will consist of lobectomy, sleeve lobectomy, bi-lobectomy, pneumonectomy, intrapericardial pneumonectomy, wedge resection or segmentectomy. Adjuvant chemotherapy and post-operative RT are permitted as indicated prior to study enrollment.

Cycle = 3 weeks (21 days).

Arm A
- Crizotinib 250 mg PO BID, Days 1-21.
- Repeat cycles every 21 days.
- Continue until recurrence, unacceptable toxicity, or up to 2 years.

Arm B
- Observation.

Note: Doses should be taken whole, 12 hours apart, with or without food. Doses will not be made up.

Number of Participants: 168

Patient Enrollment
All Sites: Oncology Patient Enrollment Network (OPEN) https://open.ctsu.org

Protocol Information

Please Enroll Your Eligible Patients!
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Schema

Eligibility:
- ALK positive patients
- Stage IB (≥ 4 cm/III/IIIA NSCLC
- Complete surgical resection
- Patient registered to ALCHEMIST Screening Trial (A151216)

Stratification:
1. Stage (IB ≥ 4 cm/IIIA)
2. Prior radiation therapy (yes vs. no)
3. Gender (male vs. female)

Arm A
Crizotinib 250 mg po BID
Days 1-21
Until recurrence, unacceptable toxicity, or up to 2 years

Arm B*
OBSERVATION

Long-Term Follow-up